{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:34:35Z","timestamp":1793687675720,"version":"4.5.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:00:00Z","timestamp":1721520000000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015722","name":"Centre Hospitalier Universitaire de Clermont-Ferrand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cgh.2022.08.011","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T18:54:23Z","timestamp":1660762463000},"page":"2338-2346.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-409X","authenticated-orcid":false,"given":"Anthony","family":"Buisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nachury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Reymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Yzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Payen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Laugie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Manlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.08.011_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2014.09.015","article-title":"Development of the L\u00e9mann index to assess digestive tract damage in patients with Crohn\u2019s disease","volume":"148","author":"Pariente","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.08.011_bib2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.08.011_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.08.011_bib4","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.08.011_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.08.011_bib6","doi-asserted-by":"crossref","unstructured":"Buisson A, Serrero M, Orsat L, et\u00a0al. Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study. Published online July 11, 2022. Inflamm Bowel Dis. doi:10.1093\/ibd\/izac119","DOI":"10.1093\/ibd\/izac119"},{"key":"10.1016\/j.cgh.2022.08.011_bib7","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.08.011_bib8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/apt.16605","article-title":"Loss of response to anti-TNF\u03b1 agents depends on treatment duration in patients with inflammatory bowel disease","volume":"54","author":"Schultheiss","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.08.011_bib9","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","volume":"60","author":"Westhovens","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2022.08.011_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S2468-1253(20)30392-7","article-title":"From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative","volume":"6","author":"Verma","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.08.011_bib11","first-page":"118","article-title":"Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results","volume":"114","author":"Arg\u00fcelles-Arias","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.cgh.2022.08.011_bib12","doi-asserted-by":"crossref","unstructured":"Smith PJ, Critchley L, Storey D, et\u00a0al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab (Ct-P13): a multi-centre cohort study. Published online April 7, 2022. J Crohns Colitis. doi:10.1093\/ecco-jcc\/jjac053","DOI":"10.1093\/ecco-jcc\/jjac053"},{"key":"10.1016\/j.cgh.2022.08.011_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2022.08.011_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ecco-jcc\/jjac009","article-title":"Introduction of subcutaneous infliximab CT-P13 and vedolizumab in clinical practice: a multi-stakeholder position statement highlighting the need for post-marketing studies","volume":"16","author":"Fierens","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.08.011_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.16852","article-title":"Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn\u2019s disease","volume":"56","author":"Roblin","year":"2022","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522007765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522007765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:42Z","timestamp":1761543822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522007765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1542356522007765"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.08.011","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute","name":"copyright","label":"Copyright"}]}}